

# Chad A Bousman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/623987/publications.pdf>

Version: 2024-02-01

172  
papers

4,865  
citations

101543

36  
h-index

138484

58  
g-index

178  
all docs

178  
docs citations

178  
times ranked

7224  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders. <i>Psychological Medicine</i> , 2022, 52, 3097-3115.	4.5	7
2	Psychotropic prescribing rates and pharmacogenomic testing implications for autism in the Canadian primary care sentinel surveillance network. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 94-100.	1.5	1
3	Disruptions in white matter microstructure associated with impaired visual associative memory in schizophrenia-spectrum illness. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 971-983.	3.2	3
4	Perspectives on the Clinical Use of Pharmacogenetic Testing in Late-Life Mental Healthcare: A Survey of the American Association of Geriatric Psychiatry Membership. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 560-571.	1.2	3
5	Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. <i>Molecular Psychiatry</i> , 2022, 27, 593-605.	7.9	13
6	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 1295-1305.	2.3	10
7	Encountering Pharmacogenetic Test Results in the Psychiatric Clinic. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 95-100.	1.9	4
8	Systematic Review and Meta-Analysis of L-Methylfolate Augmentation in Depressive Disorders. <i>Pharmacopsychiatry</i> , 2022, 55, 139-147.	3.3	5
9	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110550.	4.8	5
10	Editorial: Pharmacogenomics: From Bench to Bedside and Back Again. <i>Frontiers in Genetics</i> , 2022, 13, 878191.	2.3	0
11	Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. <i>Translational Psychiatry</i> , 2022, 12, 145.	4.8	12
12	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
13	Whole-genome sequencing analysis of clozapine-induced myocarditis. <i>Pharmacogenomics Journal</i> , 2022, 22, 173-179.	2.0	1
14	Pharmacogenetic Testing Knowledge and Attitudes among Pediatric Psychiatrists and Pediatricians in Alberta, Canada. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2022, 31, 18-27.	0.6	0
15	Dispensing patterns of mental health medications before and during the COVID-19 pandemic in Alberta, Canada: An interrupted time series analysis. <i>International Journal of Psychiatry in Medicine</i> , 2022, , 009121742210848.	1.8	1
16	Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic. , 2022, 1, .		3
17	Individual deviations from normative models of brain structure in a large cross-sectional schizophrenia cohort. <i>Molecular Psychiatry</i> , 2021, 26, 3512-3523.	7.9	78
18	Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 660-664.	0.5	26

#	ARTICLE	IF	CITATIONS
19	<i>CYP2D6</i> and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 33-45.	1.3	15
20	Successful Clozapine Rechallenge After Suspected Clozapine-Associated Myocarditis. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 218-220.	1.4	12
21	Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations. <i>Frontiers in Pharmacology</i> , 2021, 12, 636650.	3.5	22
22	Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 595-607.	3.2	40
23	Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (TRON): A 20-week, open label pilot study. <i>CNS Spectrums</i> , 2021, , 1-35.	1.2	4
24	Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 172-176.	1.5	1
25	Brain morphology is differentially impacted by peripheral cytokines in schizophrenia-spectrum disorder. <i>Brain, Behavior, and Immunity</i> , 2021, 95, 299-309.	4.1	15
26	Beneficial effects of natural products on female sexual dysfunction: A systematic review and meta-analysis. <i>Phytomedicine</i> , 2021, 93, 153760.	5.3	3
27	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , 2021, 54, 5-17.	3.3	96
28	Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 29-39.	1.5	8
29	Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. <i>Psychiatry Research</i> , 2021, 305, 114247.	3.3	12
30	Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1334.	2.5	16
31	Parenting – Brain Development interactions as predictors of adolescent depressive symptoms and well-being: Differential susceptibility or diathesis-stress?. <i>Development and Psychopathology</i> , 2020, 32, 139-150.	2.3	19
32	The Impact of Childhood Adversity on Cognitive Development in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2020, 46, 140-153.	4.3	31
33	Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?. <i>Pharmacopsychiatry</i> , 2020, 53, 174-178.	3.3	16
34	The Influence of Maternal Parenting Style on the Neural Correlates of Emotion Processing in Children. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2020, 59, 274-282.	0.5	44
35	EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. <i>European Journal of Nutrition</i> , 2020, 59, 2439-2447.	3.9	19
36	Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. <i>Pharmacogenomics Journal</i> , 2020, 20, 192-201.	2.0	41

#	ARTICLE	IF	CITATIONS
37	Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders. <i>Psychological Medicine</i> , 2020, 50, 1475-1489.	4.5	12
38	S-Adenosylmethionine (SAME) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. <i>Psychopharmacology</i> , 2020, 237, 209-218.	3.1	19
39	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 50-52.	4.7	22
40	Opportunities and challenges of implementation models of pharmacogenomics in clinical practice. , 2020, , 449-457.		0
41	Genetic testing in psychiatry: State of the evidence. , 2020, , 437-448.		0
42	Consumer participation in personalized psychiatry. , 2020, , 63-68.		1
43	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 921-932.	3.2	22
44	Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 288-297.	2.3	22
45	Engaging in building the educational support needed to deliver precision health in Canada. <i>Healthcare Management Forum</i> , 2020, 33, 135-139.	1.4	2
46	Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 145-152.	1.5	8
47	Reply to Dawes et al.. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 586-587.	1.9	0
48	Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study. <i>Psychiatry Research</i> , 2020, 290, 113048.	3.3	2
49	Breast Cancer Survivor Symptoms: A Comparison of Physicians'™ Consultation Records and Nurse-Led Survivorship Care Plans. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, E34-E42.	0.6	7
50	The ubiquitin proteasome system and schizophrenia. <i>Lancet Psychiatry</i> , the, 2020, 7, 528-537.	7.4	43
51	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 521-530.	1.9	32
52	Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. <i>Translational Psychiatry</i> , 2020, 10, 37.	4.8	24
53	Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 609-629.	1.2	18
54	Impact of CYP2C19 genotype-predicted enzyme activity on hippocampal volume, anxiety, and depression. <i>Psychiatry Research</i> , 2020, 288, 112984.	3.3	6

#	ARTICLE	IF	CITATIONS
55	“Black box” pharmacogenetic decision-support tools in psychiatry. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 113-115.	1.7	8
56	Assessment of Placental Cortisol Pathway Gene Expression in Term Pregnant Women with Anxiety. <i>Neuropsychobiology</i> , 2019, 77, 1-7.	1.9	6
57	The schizophrenia genetics knowledgebase: a comprehensive update of findings from candidate gene studies. <i>Translational Psychiatry</i> , 2019, 9, 205.	4.8	19
58	Towards pharmacogenetic-based treatment in psychiatry. <i>Journal of Neural Transmission</i> , 2019, 126, 1-3.	2.8	7
59	Pharmacoeugenetics of Major Depression. , 2019, , 747-754.		0
60	Exploring Heterogeneity on the Wisconsin Card Sorting Test in Schizophrenia Spectrum Disorders: A Cluster Analytical Investigation. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 750-760.	1.8	26
61	Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia. <i>American Journal of Psychiatry</i> , 2019, 176, 552-563.	7.2	97
62	Adverse effect of catechol-O-methyltransferase (COMT) Val158Met met/met genotype in methamphetamine-related executive dysfunction. <i>Addictive Behaviors</i> , 2019, 98, 106023.	3.0	7
63	Antidepressant pharmacogenetics in children and young adults: A systematic review. <i>Journal of Affective Disorders</i> , 2019, 254, 98-108.	4.1	27
64	Interrogating the Evolutionary Paradox of Schizophrenia: A Novel Framework and Evidence Supporting Recent Negative Selection of Schizophrenia Risk Alleles. <i>Frontiers in Genetics</i> , 2019, 10, 389.	2.3	21
65	Interaction between hypothalamic-pituitary-adrenal axis genetic variation and maternal behavior in the prediction of amygdala connectivity in children. <i>NeuroImage</i> , 2019, 197, 493-501.	4.2	8
66	Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 309-312.	4.7	38
67	CYP2D6 testing to guide risperidone and aripiprazole therapy. <i>Lancet Psychiatry</i> , 2019, 6, 362-364.	7.4	7
68	Blood and brain protein levels of ubiquitin-conjugating enzyme E2K (UBE2K) are elevated in individuals with schizophrenia. <i>Journal of Psychiatric Research</i> , 2019, 113, 51-57.	3.1	14
69	Moving pharmacoeugenetics tools for depression toward clinical use. <i>Journal of Affective Disorders</i> , 2019, 249, 336-346.	4.1	25
70	Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia. <i>Scientific Reports</i> , 2019, 9, 2307.	3.3	31
71	Estimating the Potential Impact of CYP2C19 and CYP2D6 Genetic Testing on Protocol-Based Care for Depression in Canada and the United States. <i>Molecular Neuropsychiatry</i> , 2019, 5, 27-33.	2.9	2
72	An Interleukin-1 beta (IL1B) haplotype linked with psychosis transition is associated with IL1B gene expression and brain structure. <i>Schizophrenia Research</i> , 2019, 204, 201-205.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Systematic review and critical appraisal of child abuse measurement instruments. <i>Psychiatry Research</i> , 2019, 272, 106-113.	3.3	73
74	Investigation of peripheral complement factors across stages of psychosis. <i>Schizophrenia Research</i> , 2019, 204, 30-37.	2.0	50
75	Insula Functional Connectivity in Schizophrenia: Subregions, Gradients, and Symptoms. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 399-408.	1.5	35
76	Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. <i>Journal of Affective Disorders</i> , 2019, 245, 1007-1015.	4.1	42
77	Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia. <i>Journal of Neural Transmission</i> , 2019, 126, 19-25.	2.8	6
78	The effects of a muscarinic receptor 1 gene variant on executive and non-executive cognition in schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2019, 273, 178-180.	3.3	2
79	Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. <i>Pharmacogenomics</i> , 2019, 20, 37-47.	1.3	126
80	Hippocampal subfields and visuospatial associative memory across stages of schizophrenia-spectrum disorder. <i>Psychological Medicine</i> , 2019, 49, 2452-2462.	4.5	17
81	Towards the integration of pharmacogenetics in psychiatry. <i>Current Opinion in Psychiatry</i> , 2019, 32, 7-15.	6.3	103
82	The role of depression pharmacogenetic decision support tools in shared decision making. <i>Journal of Neural Transmission</i> , 2019, 126, 87-94.	2.8	21
83	Pharmacogenetic Tests in Psychiatry. <i>American Journal of Psychiatry</i> , 2018, 175, 189-189.	7.2	9
84	Mind the prevalence rate: overestimating the clinical utility of psychiatric diagnostic classifiers. <i>Psychological Medicine</i> , 2018, 48, 1225-1227.	4.5	13
85	Decreased peripheral TNF alpha (TNF- $\alpha$ ) mRNA expression in patients with treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2018, 202, 387-388.	2.0	4
86	Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 1-6.	4.8	11
87	Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression?. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 125-133.	1.2	18
88	Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in Caucasians. <i>Nutritional Neuroscience</i> , 2018, 21, 589-601.	3.1	15
89	Risk and resilience brain networks in treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 284-292.	2.0	15
90	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. <i>Molecular Psychiatry</i> , 2018, 23, 1261-1269.	7.9	522

#	ARTICLE	IF	CITATIONS
91	Neuregulin-1 (<i>NRG1</i>) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia. <i>Psychological Medicine</i> , 2018, 48, 801-809.	4.5	10
92	Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities. <i>Schizophrenia Bulletin</i> , 2018, 44, 560-574.	4.3	44
93	Genetic variation in cytokine genes and risk for transition to psychosis among individuals at ultra-high risk. <i>Schizophrenia Research</i> , 2018, 195, 589-590.	2.0	6
94	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. <i>Pharmacogenomics</i> , 2018, 19, 1269-1284.	1.3	16
95	Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders. <i>Psychiatry Research - Neuroimaging</i> , 2018, 281, 61-68.	1.8	10
96	The effects of a muscarinic receptor 1 gene variant on cortical thickness and surface area in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2018, 280, 62-64.	1.8	3
97	Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care. <i>JAMA Psychiatry</i> , 2018, 75, 1090.	11.0	5
98	SimPEL: Simulationâ€based power estimation for sequencing studies of lowâ€prevalence conditions. <i>Genetic Epidemiology</i> , 2018, 42, 480-487.	1.3	0
99	Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. <i>Pharmacogenomics Journal</i> , 2018, 18, 613-622.	2.0	80
100	Reply to Searcy and colleagues. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 108-109.	1.5	0
101	Adjunctive S-adenosylmethionine (SAME) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2018, 28, 1126-1136.	0.7	29
102	White Matter Disruptions in Schizophrenia Are Spatially Widespread and Topologically Converge on Brain Network Hubs. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw100.	4.3	85
103	Polygenic phenotypic plasticity moderates the effects of severe childhood abuse on depressive symptom severity in adulthood: A 5-year prospective cohort study. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 75-81.	2.6	6
104	Functional brain networks in treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2017, 184, 73-81.	2.0	36
105	Meta-analysis reveals associations between genetic variation in the 5â€ and 3â€ regions of Neuregulin-1 and schizophrenia. <i>Translational Psychiatry</i> , 2017, 7, e1004-e1004.	4.8	32
106	Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. <i>Translational Psychiatry</i> , 2017, 7, e1037-e1037.	4.8	21
107	Antidepressant prescribing in the precision medicine era: a prescriberâ€™s primer on pharmacogenetic tools. <i>BMC Psychiatry</i> , 2017, 17, 60.	2.6	59
108	Antidepressant Pharmacogenetics. <i>American Journal of Psychiatry</i> , 2017, 174, 417-418.	7.2	10

#	ARTICLE	IF	CITATIONS
109	Accelerated Gray and White Matter Deterioration With Age in Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 286-295.	7.2	168
110	Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 1-6.	1.5	12
111	Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. <i>Translational Psychiatry</i> , 2017, 7, e1196-e1196.	4.8	49
112	Systematic evaluation of commercial pharmacogenetic testing in psychiatry. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 387-393.	1.5	56
113	Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. <i>Translational Psychiatry</i> , 2017, 7, 1280.	4.8	25
114	Peripheral Transcription of NRG-ErbB Pathway Genes Are Upregulated in Treatment-Resistant Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017, 8, 225.	2.6	20
115	Schizophrenia genetics in the genome-wide era: a review of Japanese studies. <i>NPJ Schizophrenia</i> , 2017, 3, 27.	3.6	13
116	The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Moderates the Effects of Childhood Abuse on Severity of Depressive Symptoms in a Time-Dependent Manner. <i>Frontiers in Psychiatry</i> , 2016, 7, 151.	2.6	8
117	Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment. <i>International Clinical Psychopharmacology</i> , 2016, 31, 127-133.	1.7	12
118	Commercial pharmacogenetic-based decision-support tools in psychiatry. <i>Lancet Psychiatry</i> , 2016, 3, 585-590.	7.4	110
119	Intensive residential treatment for obsessive-compulsive disorder: Outcomes and predictors of patient adherence to cognitive-behavioural therapy. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2016, 9, 82-89.	1.5	18
120	Early origins of mental disorder - risk factors in the perinatal and infant period. <i>BMC Psychiatry</i> , 2016, 16, 270.	2.6	57
121	Neuregulin-1 and schizophrenia in the genome-wide association study era. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 387-409.	6.1	68
122	Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. <i>Breast</i> , 2016, 26, 100-105.	2.2	23
123	The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. <i>NPJ Schizophrenia</i> , 2015, 1, 15043.	3.6	60
124	Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 493.	1.6	29
125	Effects of COMT, DRD2, BDNF, and APOE Genotypic Variation on Treatment Efficacy and Cognitive Side Effects of Electroconvulsive Therapy. <i>Journal of ECT</i> , 2015, 31, 129-135.	0.6	16
126	Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 53-61.	2.0	5



#	ARTICLE	IF	CITATIONS
127	Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV. <i>Journal of NeuroVirology</i> , 2015, 21, 535-543.	2.1	4
128	Effects of oxytocin and genetic variants on brain and behaviour: Implications for treatment in schizophrenia. <i>Schizophrenia Research</i> , 2015, 168, 614-627.	2.0	44
129	An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. <i>Advances in Integrative Medicine</i> , 2015, 2, 49-55.	0.9	15
130	Serotonin transporter polymorphism ( <i>5HTTLPR</i> ), severe childhood abuse and depressive symptom trajectories in adulthood. <i>BJPsych Open</i> , 2015, 1, 104-109.	0.7	5
131	Typologies of positive psychotic symptoms in methamphetamine dependence. <i>American Journal on Addictions</i> , 2015, 24, 94-97.	1.4	10
132	The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2015, 234, 182-187.	1.8	13
133	Effects of neuregulin-1 genetic variation and depression symptom severity on longitudinal patterns of psychotic symptoms in primary care attendees. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014, 165, 62-67.	1.7	8
134	Escitalopram Efficacy in Depression. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 645-648.	1.4	21
135	Antidepressant pharmacogenetics. <i>Current Opinion in Psychiatry</i> , 2014, 27, 43-51.	6.3	40
136	Methylenetetrahydrofolate reductase ( <i>MTHFR</i> ) genetic variation and major depressive disorder prognosis: A five-year prospective cohort study of primary care attendees. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014, 165, 68-76.	1.7	20
137	G-protein $\beta 3$ subunit genetic variation moderates five-year depressive symptom trajectories of primary care attendees. <i>Journal of Affective Disorders</i> , 2014, 165, 64-68.	4.1	2
138	Kava for the Treatment of Generalized Anxiety Disorder RCT: Analysis of Adverse Reactions, Liver Function, Addiction, and Sexual Effects. <i>Phytotherapy Research</i> , 2013, 27, 1723-1728.	5.8	81
139	Psychomotor depressive symptoms may differentially respond to venlafaxine. <i>International Clinical Psychopharmacology</i> , 2013, 28, 121-126.	1.7	13
140	Kava in the Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 643-648.	1.4	99
141	Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8-weeks in major depression. <i>Human Psychopharmacology</i> , 2013, 28, 516-522.	1.5	36
142	High impact child abuse may predict risk of elevated suicidality during antidepressant initiation. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 1191-1195.	2.3	8
143	Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis. <i>Translational Psychiatry</i> , 2013, 3, e251-e251.	4.8	31
144	Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 95.	3.7	36

#	ARTICLE	IF	CITATIONS
145	Negative Symptoms of Psychosis Correlate with Gene Expression of the Wnt/ $\beta$ -Catenin Signaling Pathway in Peripheral Blood. <i>Psychiatry Journal</i> , 2013, 2013, 1-4.	1.5	14
146	Oestrogen Alpha-Receptor Variant and Two-Year Memory Decline in Midlife Australian Women. <i>Neuropsychobiology</i> , 2012, 66, 259-265.	1.9	4
147	ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. <i>Translational Psychiatry</i> , 2012, 2, e198-e198.	4.8	61
148	The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. <i>Human Psychopharmacology</i> , 2012, 27, 262-269.	1.5	26
149	Chronic Illness Histories of Adults Entering Treatment for Co-occurring Substance Abuse and Other Mental Health Disorders. <i>American Journal on Addictions</i> , 2012, 21, 1-4.	1.4	11
150	Alpha $\alpha$ 5 and $\alpha$ 3 nicotinic receptor gene variants predict nicotine dependence but not cessation: Findings from the COMMIT cohort. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 227-235.	1.7	16
151	Assessing Neuropsychological Performance in a Migrant Farm Working Colonia in Baja California, Mexico: A Feasibility Study. <i>Journal of Immigrant and Minority Health</i> , 2011, 13, 742-747.	1.6	2
152	Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. <i>Journal of NeuroVirology</i> , 2011, 17, 239-247.	2.1	35
153	Characteristics of Homeless Youth Attending Two Different Youth Drop-In Centers. <i>Youth and Society</i> , 2011, 43, 28-43.	2.3	14
154	Methamphetamine-Associated Psychosis: A Model for Biomarker Discovery in Schizophrenia. , 2011, , 327-343.		6
155	Formidable Challenges in the Search for Biomarkers of Psychiatric Disorders. <i>Metabolomics: Open Access</i> , 2011, 01, .	0.1	2
156	Homelessness and Neuropsychological Impairment. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 790-794.	1.0	14
157	Correlation of major depressive disorder symptoms with FKBP5 but not FKBP4 expression in human immunodeficiency virus-infected individuals. <i>Journal of NeuroVirology</i> , 2010, 16, 399-404.	2.1	21
158	Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: Convergent pathway analysis findings from two independent samples. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 494-502.	1.7	97
159	Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1336-1341.	1.7	54
160	Exploration of a genomic expression and pathway analysis approach to neurocognitive performance: preliminary findings. <i>Neurobehavioral HIV Medicine</i> , 2010, , 23.	2.0	0
161	Impact of COMT Val158Met on executive functioning in the context of HIV and methamphetamine. <i>Neurobehavioral HIV Medicine</i> , 2010, 2010, 1.	2.0	15
162	COMT Val158Met Polymorphism, Executive Dysfunction, and Sexual Risk Behavior in the Context of HIV Infection and Methamphetamine Dependence. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2010, 2010, 1-9.	1.4	23

#	ARTICLE	IF	CITATIONS
163	Preliminary evidence of motor impairment among polysubstance 3,4-methylenedioxymethamphetamine users with intact neuropsychological functioning. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 1047-1055.	1.8	6
164	Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 890-901.	1.8	39
165	Preliminary evidence of ethnic divergence in associations of putative genetic variants for methamphetamine dependence. <i>Psychiatry Research</i> , 2010, 178, 295-298.	3.3	18
166	Formative Assessment of ARM-U: A Modular Intervention for Decreasing Risk Behaviors Among HIV-Positive and HIV-Negative Methamphetamine-Using MSM. <i>Open AIDS Journal</i> , 2010, 4, 105-115.	0.5	12
167	Negative mood and sexual behavior among non-monogamous men who have sex with men in the context of methamphetamine and HIV. <i>Journal of Affective Disorders</i> , 2009, 119, 84-91.	4.1	46
168	Genetic association studies of methamphetamine use disorders: A systematic review and synthesis. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 1025-1049.	1.7	70
169	Predictors of Weapon Carrying in Youth Attending Drop-in Centers. <i>American Journal of Health Behavior</i> , 2009, 33, 745-58.	1.4	10
170	Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study (Supplementary Table). <i>Current Pharmacogenomics and Personalized Medicine</i> , 2009, 7, 164-188.	0.2	44
171	Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2007, 90, 159-165.	3.2	54
172	Predictors of substance use among homeless youth in San Diego. <i>Addictive Behaviors</i> , 2005, 30, 1100-1110.	3.0	84